Compounds useful for treating hepatitis C virus

A compound of Formula I

• wherein:
• Q is N;
• R1 is tetrazolyl, MeCONHSO2—, PhCONHSO2—, R5O2C(CH2)0-3CONHSO2—,
• R2 is
• —CH2Ar1, —CHPh2, —CH2CO(4-FPh), —CH2CO(4-CF3Ph), or —CH2CONp where Np is naphthyl;
• R3 is C5-7cycloalkyl;
• R4 is hydrogen, Ar2, or Ar3;
• Ar1 is selected from the following group:
• phenyl, halophenyl,
• Ar2 is phenyl, naphthyl, or biphenyl, optionally substituted with 1-3 substituents selected from the group comprising halogen, C1-6 alkyl, hydroxyC1-6alkyl, C1-6alkoxy, C1-6sulfoxy, C1-2perfluoroalkyl, hydroxy, formyl, C1-6alkylcarbonyl, cyano, nitro, C1-6alkylamido, CO2R5, CONR5R5, C1-6alkylsulfonamido, and dioxolane;
• Ar3 is thienyl, furanyl, pyrrolyl, benzothiophenyl, benzofuranyl, indolyl, quinolinyl, or pyrimidinyl optionally substituted with 1-2 substituents selected from the group comprising C1-6alkyl, formyl, acetoxy, trifluoroacetoxy, and t-butoxycarbonyl;
• R5 is hydrogen or C1-6alkyl;
• R6 is halogen, methoxy, CO2R5 or CONR7R8;
• R7 and R8 are independently hydrogen, C1-6alkyl, —CH(Me)CO2R5, —(CH2)1-3CO2R5, —(CH2)1-3CONR5R5, —(CH2)1-3OH,
• or R7 and R8 taken together with the nitrogen to which they are attached form pyrrolidine, morpholine, piperidine, 4-hydroxypiperidine, piperazine, or 4-methylpiperazine;
• or a pharmaceutically acceptable salt, solvate, or prodrug thereof.